Global Immunofluorescence in Autoimmune Diseases Market, By Product (Reagents, Instruments, Antibodies, Kits, Consumables and Accessories), Type (Indirect Immunofluorescence, Direct Immunofluorescence), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers, Contract Research Organizations)– Industry Trends and Forecast to 2029.
Immunofluorescence in Autoimmune Diseases Market Analysis and Size
According to American Autoimmune Related Diseases Association (AARDA) more than 80 autoimmune diseases have been confirmed. Due to their ability to identify autoantibodies ‘in vivo’ immunofluorescence tests (IF) are crucial diagnostic tools for identifying acquired autoimmune blistering disorders. Since the early 1960s, IF techniques have become effective methods for diagnosing autoimmune blistering conditions. They are still considered for this purpose because of their role in the differential diagnosis of difficult-to-distinguish clinical bullous diseases and their positive therapeutic implications. In addition, follow-ups and clarification of suspected epitope spreading cases benefit from the use of IF methods.
Data Bridge Market Research analyses that the immunofluorescence in autoimmune diseases market which was USD 4,253.30 million in 2021, would rocket up to USD 6627.14 million by 2029, and is expected to undergo a CAGR of 5.70% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Immunofluorescence in Autoimmune Diseases Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Reagents, Instruments, Antibodies, Kits, Consumables and Accessories), Type (Indirect Immunofluorescence, Direct Immunofluorescence), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers, Contract Research Organizations)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc. (U.S.), Abcam plc. (U.K.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), Merck KGaA (Germany), Inova Diagnostics, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), MEDIPAN GmbH (Germany), Sino Biological Inc. (China), Enzo Life Sciences, Inc. (U.S.), BD (U.S.), TCS Biosciences Ltd. (U.K.), Siemens (Germany), Grifols, S.A (Spain), Trinity Biotech (Ireland), HYCOR Biomedical (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Autoimmune illnesses develop when the immune system does not recognise the body's tissues and cells as belonging to it, instead, the immune system launches an immunological reaction against the tissues. Autoimmune disorders can affect different body regions and interfere with the normal growth and development of organs, depending on the type of sickness a person.
Immunofluorescence in Autoimmune Diseases Market Dynamics
Drivers
- Increasing cases of chronic diseases
In the forecast period of 2022–2029, rising rates of chronic diseases among an expanding population, rising levels of investment in research activities, and rising healthcare costs due to the need for better healthcare facilities will likely contribute to the market for immunofluorescence in autoimmune diseases growing.
- Research and development activities
The key factors driving the growth of the immunofluorescence market are the rising number of patients suffering from various chronic diseases and increased spending on healthcare infrastructure and improving healthcare quality. The focus of numerous businesses and organisations on improving their research and development results in significant costs being paid for the same, which also accelerates the market's growth.
- Increase in healthcare insaurance
Growing healthcare insurance and other medical reimbursement facilities are expected to generate profitable opportunities for the market.
Opportunities
Increasing applications from developing nations will open up more chances, which will fuel the market for immunofluorescence in autoimmune illnesses throughout the forecast period.
Restraints/Challenges
Increasing instrument costs and rising excise taxes levied by the U.S. government would restrain the market's expansion for immunofluorescence in autoimmune illnesses over the forecast period.
This immunofluorescence in autoimmune diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunofluorescence in autoimmune diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Immunofluorescence in Autoimmune Diseases Market
Patients suffering from autoimmune diseases worried that the COVID-19 would have serious side effects or make their condition worse while the epidemic was going on. So, some people may have a higher risk of developing severe COVID-19. As a result, the medical professionals who cared for the patients continuously made frequent diagnoses of autoimmune diseases, which aided in the development of the market.
Global Immunofluorescence in Autoimmune Diseases Market Scope
The immunofluorescence in autoimmune diseases market is segmented on the basis of product, type, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reagents
- Instruments
- Antibodies
- Kits
- Consumables
- Accessories
Type
- Indirect Immunofluorescence
- Direct Immunofluorescence
End User
- Pharmaceutical
- Biotechnology Companies
- Academic and Research Institutes
- Hospitals
- Diagnostic Centers
- Contract Research Organizations
Immunofluorescence in Autoimmune Diseases Market Regional Analysis/Insights
The immunofluorescence in autoimmune diseases market is analysed and market size insights and trends are provided by country, product, type, and end-user as referenced above.
The countries covered in the immunofluorescence in autoimmune diseases market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the high prevalence of chronic diseases among the rising population along with rising research activities.
Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period of 2022 to 2029 owed to the large untapped potential market, improving healthcare infrastructure and growing healthcare spending.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Immunofluorescence in Autoimmune Diseases Market Share Analysis
The immunofluorescence in autoimmune diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunofluorescence in autoimmune diseases market.
Some of the major players operating in the immunofluorescence in autoimmune diseases market are:
- Thermo Fisher Scientific Inc. (U.S.)
- Abcam plc. (U.K.)
- Bio-Rad Laboratories, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Merck KGaA (Germany)
- Inova Diagnostics, Inc. (U.S.)
- Cell Signaling Technology, Inc. (U.S.)
- MEDIPAN GmbH (Germany)
- Sino Biological Inc. (China)
- Enzo Life Sciences, Inc. (U.S.)
- BD (U.S.)
- TCS Biosciences Ltd. (U.K.)
- Siemens (Germany)
- Grifols, S.A (Spain)
- Trinity Biotech (Ireland)
- HYCOR Biomedical (U.S.)
SKU-